, Volume 163, Issue 4, pp 191–202

Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis

  • Valério R. Aquino
  • Luciano Z. Goldani
  • Alesssandro C. Pasqualotto
Original Paper


The diagnosis of invasive fungal infections (IFI) remains a challenge, particularly for diseases caused by filamentous fungi such as Aspergillus species. Unfortunately, many patients affected by these conditions are not identified before autopsy. Therefore, there is a need for new diagnostic methods for IFI. Galactomannan is a soluble antigen released during hyphal growth in tissues. A commercially available sandwich ELISA assay that detects galactomannan has been used in Europe for many years and is now approved for use in the USA. The test has an excellent negative predictive value in the detection of invasive aspergillosis (IA) in high-risk patients. In addition, it is more sensitive than culture and allows IA to be diagnosed before clinical manifestations occur. However, false-negative and false-positive results in certain populations are the main limitations to its use. The purpose of this review is to summarize the current knowledge about galactomannan testing in patients at risk for IA.


Aspergillosis Bone marrow transplantation Galactomannan Invasive fungal infections Solid organ transplantation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, Bennett JE, Walsh TJ, Patterson TF, Pankey GA. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000;30:696–709.PubMedCrossRefGoogle Scholar
  2. 2.
    Bhatti Z, Shaukat A, Almyroudis NG, Segal BH. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia 2006;162:1–15.PubMedCrossRefGoogle Scholar
  3. 3.
    Klont RR, Mennink-Kersten MA, Verweij PE. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis 2004;39:1467–74.PubMedCrossRefGoogle Scholar
  4. 4.
    Maertens J, Verhaegen J, Demuynck H, Brock P, Verhoef G, Vandenberghe P, van Eldere J, Verbist L, Boogaerts M. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999;37:3223–8.PubMedGoogle Scholar
  5. 5.
    Stynen D, Goris A, Sarfati J, Latge JP. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol 1995;33:497–500PubMedGoogle Scholar
  6. 6.
    Latge JP, Kobayashi H, Debeaupuis JP, Diaquin M, Sarfati J, Wieruszeski JM, Parra E, Bouchara JP, Fournet B. Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus. Infect Immun 1994;62:5424–33.PubMedGoogle Scholar
  7. 7.
    Bahia MC, Vieira RP, Mulloy B, Hartmann R, Bergter EB. The structures of polysaccharides and glycolipids of Aspergillus fumigatus grown in the presence of human serum. Mycopathologia 1997;137:17–25.PubMedCrossRefGoogle Scholar
  8. 8.
    Mennink-kersten MASH, Ruegebrink D, Klont RR, Blijlevens NMA, Donnelly JP, Verweij PE. Improved detection of circulating Aspergillus antigen using a new pre-treatment procedure. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC, USA; 2005.Google Scholar
  9. 9.
    Kappe R, Schulze-Berge A. New cause for false-positive results with the Pastorex Aspergillus antigen latex agglutination test. J Clin Microbiol 1993;31:2489–90.PubMedGoogle Scholar
  10. 10.
    Swanink CM, Meis JF, Rijs AJ, Donnelly JP, Verweij PE. Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol 1997;35:257–60.PubMedGoogle Scholar
  11. 11.
    Mennink-kersten MASH, Ruegebrink D, Klont RR, Verweij PE. Release of galactofuranose antigens by different Aspergillus species. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC, USA; 2005: Abstract M-153.Google Scholar
  12. 12.
    Hope WW, Kruhlak MJ, Lyman CA, Petraitiene R, Petraitis V, Francesconi A, Kasai M, Mickiene D, Sein T, Peter J, Kelaher AM, Hughes JE, Cotton MP, Cotten CJ, Bacher J, Tripathi S, Bermudez L, Maugel TK, Zerfas PM, Wingard JR, Drusano GL, Walsh TJ. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in␣vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis 2007;195:455–66.PubMedCrossRefGoogle Scholar
  13. 13.
    Becker MJ, de Marie S, Willemse D, Verbrugh HA, Bakker-Woudenberg IA. Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model. J Clin Microbiol 2000;38:1434–8.PubMedGoogle Scholar
  14. 14.
    Kauffman HF, Beaumont F, Meurs H, van der Heide S, de Vries K. Comparison of antibody measurements against Aspergillus fumigatus by means of double-diffusion and enzyme-linked immunosorbent assay (ELISA). J Allergy Clin Immunol 1983;72:255–61.PubMedCrossRefGoogle Scholar
  15. 15.
    Raad I, Hanna H, Huaringa A, Sumoza D, Hachem R, Albitar M. Diagnosis of invasive pulmonary aspergillosis using polymerase chain reaction-based detection of Aspergillus in BAL. Chest 2002;121:1171–6.PubMedCrossRefGoogle Scholar
  16. 16.
    McWhinney PH, Kibbler CC, Hamon MD, Smith OP, Gandhi L, Berger LA, Walesby RK, Hoffbrand AV, Prentice HG. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years’ experience. Clin Infect Dis 1993;17:397–404.PubMedGoogle Scholar
  17. 17.
    Bretagne S, Costa JM, Marmorat-Khuong A, Poron F, Cordonnier C, Vidaud M, Fleury-Feith J. Detection of Aspergillus species DNA in bronchoalveolar lavage samples by competitive PCR. J Clin Microbiol 1995;33:1164–8.PubMedGoogle Scholar
  18. 18.
    Denning DW, Follansbee SE, Scolaro M, Norris S, Edelstein H, Stevens DA. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991;324:654–62.PubMedCrossRefGoogle Scholar
  19. 19.
    Becker MJ, Lugtenburg EJ, Cornelissen JJ, van der Schee C, Hoogsteden HC, de Marie S. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003;121:448–57.PubMedCrossRefGoogle Scholar
  20. 20.
    Lombardi G, Farina C, Andreoni S, d’Antonio D, Faggi E, Manso E, Mazzoni A. Multicenter evaluation of an enzyme immunoassay (Platelia Aspergillus) for the detection of Aspergillus antigen in serum. Mycopathologia 2002;155:129–33.PubMedCrossRefGoogle Scholar
  21. 21.
    Ansorg R, heintschel von Heinegg R, Rath PM. Aspergillus antigenuria compared to antigenemia in bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994;13:582–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Hopwood V, Johnson EM, Cornish JM, Foot AB, Evans EG, Warnock DW. Use of the Pastorex Aspergillus antigen latex agglutination test for the diagnosis of invasive aspergillosis. J Clin Pathol 1995;48:210–213.PubMedGoogle Scholar
  23. 23.
    Verweij PE, Latge JP, Rijs AJ, Melchers WJ, de Pauw BE, Hoogkamp-Korstanje JA, Meis JF. Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies. J Clin Microbiol 1995;33:3150–3.PubMedGoogle Scholar
  24. 24.
    Sanguinetti M, Posteraro B, Pagano L, Pagliari G, Gianchi L, Mele L, La Sorda M, Franco A, Fadda G. Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 2003;41:3922–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Stynen D, Sarfati J, Goris A, Prevost MC, Lesourd M, Kamphuis H, Darras V, Latge JP. Rat monoclonal antibodies against Aspergillus galactomannan. Infect Immun 1992;60:2237–45.PubMedGoogle Scholar
  26. 26.
    Rogers TR, Haynes KA, Barnes RA. Value of antigen detection in predicting invasive pulmonary aspergillosis. Lancet 1990;336:1210–3.PubMedCrossRefGoogle Scholar
  27. 27.
    Dupont B, Huber M, Kim SJ, Bennett JE. Galactomannan antigenemia and antigenuria in aspergillosis: studies in patients and experimentally infected rabbits. J Infect Dis 1987;155:1–11.PubMedGoogle Scholar
  28. 28.
    Haynes KA, Latge JP, Rogers TR. Detection of Aspergillus antigens associated with invasive infection. J Clin Microbiol 1990;28:2040–4.PubMedGoogle Scholar
  29. 29.
    Bennett JE, Friedman MM, Dupont B. Receptor-mediated clearance of Aspergillus galactomannan. J Infect Dis 1987;155:1005–10.PubMedGoogle Scholar
  30. 30.
    Machetti M, Zotti M, Veroni L, Mordini N, van Lint MT, Bacigalupo A, Paola D, Viscoli C. Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole. Transpl Infect Dis 2000;2:140–4.PubMedCrossRefGoogle Scholar
  31. 31.
    Verweij PE, Brinkman K, Kremer HP, Kullberg BJ, Meis JF. Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. J Clin Microbiol 1999;37:1186–9.PubMedGoogle Scholar
  32. 32.
    Kami M, Ogawa S, Kanda Y, Tanaka Y, Machida U, Matsumura T, Sakamaki H, Hirai H. Early diagnosis of central nervous system aspergillosis using polymerase chain reaction, latex agglutination test, and enzyme-linked immunosorbent assay. Br J Haematol 1999;106:536–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Maertens J, Verhaegen J, Lagrou K, van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001;97:1604–10.PubMedCrossRefGoogle Scholar
  34. 34.
    Sulahian A, Boutboul F, Ribaud P, Leblanc T, Lacroix C, Derouin F. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 2001;91:311–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Verweij PE, Dompeling EC, Donnelly JP, Schattenberg AV, Meis JF. Serial monitoring of Aspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples. Infection 1997;25:86–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Williamson EC, Oliver DA, Johnson EM, Foot AB, Marks DI, Warnock DW. Aspergillus antigen testing in bone marrow transplant recipients. J Clin Pathol 2000;53:362–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Pazos C, Ponton J, del Palacio A. Contribution of (1→3)-Beta-d-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005;43:299–305.PubMedCrossRefGoogle Scholar
  38. 38.
    Francesconi A, Kasai M, Petraitiene R, Petraitis V, Kelaher AM, Schaufele R, Hope WW, Shea YR, Bacher J, Walsh TJ. Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis. J Clin Microbiol 2006;44:2475–80.PubMedCrossRefGoogle Scholar
  39. 39.
    Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag E, Shah PM, Stevens DA, Walsh TJ. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7–14.PubMedCrossRefGoogle Scholar
  40. 40.
    Maertens J. Galactomannan antigen detection in invasive aspergillosis: test optimisation and impact on patient management. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Nice, France; 2006. p. s278.Google Scholar
  41. 41.
    Patterson TF, Miniter P, Ryan JL, Andriole VT. Effect of immunosuppression and amphotericin b on Aspergillus antigenemia in an experimental model. J Infect Dis 1988;158:415–22.PubMedGoogle Scholar
  42. 42.
    Maurer JR, Tullis DE, Grossman RF, Vellend H, Winton TL, Patterson GA. Infectious complications following isolated lung transplantation. Chest 1992;101:1056–9.PubMedGoogle Scholar
  43. 43.
    Fortun J, Martin-Davila P, Alvarez ME, Sanchez-sousa A, Quereda C, Navas E, Barcena R, Vicente E, Candelas A, Honrubia A, Nuno J, Pintado V, Moreno S. Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients. Transplantation 2001;71:145–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Kwak EJ, Husain S, Obman A, Meinke L, Stout J, Kusne S, Wagener MM, Singh N. Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 2004;42:435–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Husain S, Kwak EJ, Obman A Wagener MM, Kusne S, Stout JE, McCurry KR, Singh N. Prospective assessment of platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004;4:796–802.PubMedCrossRefGoogle Scholar
  46. 46.
    Pereira CN, del Nero G, Lacaz CS, Machado CM. The contribution of galactomannan detection in the diagnosis of invasive aspergillosis in bone marrow transplant recipients. Mycopathologia 2005;159:487–93.PubMedCrossRefGoogle Scholar
  47. 47.
    Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F, Villard O, Liu KL, Natarajan-Ame S, Lutz P, Dufour P, Bergerat JP, Candolfi E. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002;20:1898–906.PubMedCrossRefGoogle Scholar
  48. 48.
    Herbrecht R, Moghaddam A, Mahmal L, Natarajan-ame A, Fornecker LM, Letscher-Bru V. Invasive aspergillosis in the hematologic and immunologic patient: new findings and key questions in leukemia. Med Mycol 2005;43 Suppl 1:s239–42.PubMedGoogle Scholar
  49. 49.
    Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006;42:1417–727.PubMedCrossRefGoogle Scholar
  50. 50.
    Balloy V, Huerre M, Latge JP, Chignard M. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005;73:494–503.PubMedCrossRefGoogle Scholar
  51. 51.
    Mennink-Kersten MA, Donnelly JP, Verweij PE. Retection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004;4:349–57.PubMedCrossRefGoogle Scholar
  52. 52.
    Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 1999;78:123–38.CrossRefGoogle Scholar
  53. 53.
    Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004;190:641–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Petraitis V, Petraitiene R, Sarafandi AA, Kelaher AM, Lyman CA, Casler HE, Sein R, Groll AH, Bacher J, Avila NA, Walsh TJ. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003;187:1834–43.PubMedCrossRefGoogle Scholar
  55. 55.
    Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005;40:1762–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Verweij PE, Masson C, Klont R, Heinen C, Crepin B, Maertens J. Optimisation of the cut-off value of the Platelia Aspergillus ELISA. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Nice, France; 2006. p. s277.Google Scholar
  57. 57.
    Racil Z, Kocmanova I, Kubicova E, Lochmanova J, Sevcikova A, Mayer J. Variation of galactomannan level during 24-hour period in haematooncological patients with/without invasive aspergillosis. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Nice; 2006. p. 729.Google Scholar
  58. 58.
    Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005;5:609–22.PubMedCrossRefGoogle Scholar
  59. 59.
    Maertens J, Theunissen K, Deeren D, Meersseman W, van Eldere J. Defining a case of invasive aspergillosis by serum galactomannan. Med Mycol 2006;44 Suppl:173–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Pasqualotto AC, Denning DW. Post-operative aspergillosis. Clin Microbiol Infect 2006;12:1060–76.PubMedCrossRefGoogle Scholar
  61. 61.
    Maertens J, Theunissen K, Verbeken E, Lagrou K, Verhaegen J, Boogaerts M, Eldere JV. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004;126:852–60.PubMedCrossRefGoogle Scholar
  62. 62.
    Ansorg R, van den Boom R, Rath PM. Detection of Aspergillus galactomannan antigen in foods and antibiotics. Mycoses 1997;40:353–7.PubMedGoogle Scholar
  63. 63.
    Adam O, Auperin A, Wilquin F, Bourhis JH, Gachot B, Chachaty E. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 2004;38:917–20.PubMedCrossRefGoogle Scholar
  64. 64.
    Mattei F, Rapezzi D, Mordini N, Cuda F, Lo Nigro C, Musso M, Arnelli A, Cagnassi S, Gallamini A. False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in␣vivo during amoxicillin-clavulanic acid treatment. J Clin Microbiol 2004;42:5362–3.PubMedCrossRefGoogle Scholar
  65. 65.
    Viscoli C, Machetti M, Cappellano P, Bucci B, Bruzzi P, Van Lint MT, Bacigalupo A. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004;38:913–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003;349:2366–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Bart-Delabesse E, Basile M, Al Jijakli A, Souville D, Gay F, Philippe B, Bossi P, Danis M, Vernant JP, Datry A. Detection of Aspergillus galactomannan antigenemia to determine biological and clinical implications of Beta-lactam treatments. J Clin Microbiol 2005;43:5214–20.PubMedCrossRefGoogle Scholar
  68. 68.
    Yucesoy M, Ergon MC. Detection of Aspergillus galactomannan antigen levels for antimicrobial agents by ELISA. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Nice, France; 2006: Poster 869.Google Scholar
  69. 69.
    Singh N, Obman A, Husain S, Aspinall S, Mietzner S, Stout JE. Reactivity of Platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum. Antimicrob Agents Chemother 2004;48:1989–92.PubMedCrossRefGoogle Scholar
  70. 70.
    Machetti M, Majabo MJ, Furfaro E, Solari N, Novelli A, Cafiero F, Viscoli C. Kinetics of galactomannan in surgical patients receiving perioperative piperacillin/tazobactam prophylaxis. J Antimicrob Chemother 2006;58:806–10.PubMedCrossRefGoogle Scholar
  71. 71.
    Aubry A, Porcher R, Bottero J, Touratier S, Leblanc T, Brethon B, Rousselot P, Raffoux E, Menotti J, Derouin F, Ribaud P, Sulahian A. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with Beta-lactam antibiotics in patients with hematological disorders. J Clin Microbiol 2006;44:389–94.PubMedCrossRefGoogle Scholar
  72. 72.
    Rohrlich P, Sarfati J, Mariani P, Duval M, Carol A, Saint-Martin C, Bingen E, Latge JP, Vilmer E. Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis. Pediatr Infect Dis J 1996;15:232–7.PubMedCrossRefGoogle Scholar
  73. 73.
    Rollides E. Early diagnosis of invasive aspergillosis in small children. 2nd advances against aspergillosis (AAA). Greece, Athens; 2006.Google Scholar
  74. 74.
    Siemann M, Koch-Dorfler M, Gaude M. False-positive results in premature infants with the Platelia Aspergillus sandwich enzyme-linked immunosorbent assay. Mycoses 1998;41:373–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Mennink-Kersten MA, Klont RR, Warris A, Op den Camp HJ, Verweij PE. Bifidobacterium lipoteichoic acid and false ELISA reactivity in Aspergillus antigen detection. Lancet 2004;363:325–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Letscher-Bru V, Cavalier A, Pernot-Marino E, Koenig H, Eyer D, Waller J, Candolfi E. Aspergillus galactomannan antigen detection with platelia® Aspergillus: multiple positive antigenemia without Aspergillus infection. L Mycologie Medicale 1998;8:112–3.Google Scholar
  77. 77.
    El Saleeby CM, Allison KJ, Knapp KM, Walsh TJ, Hayden RT. Discordant rise in galactomannan antigenemia in a patient with resolving aspergillosis, renal failure, and ongoing hemodialysis. J Clin Microbiol 2005;43:3560–3.PubMedCrossRefGoogle Scholar
  78. 78.
    Hamaki T, Kami M, Kanda Y, Miyakoshi S, Ueyama J, Morinaga S, Mutou Y. False-positive results of Aspergillus enzyme-linked immunosorbent assay in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001;28:633–4.PubMedCrossRefGoogle Scholar
  79. 79.
    Muquim A, Dial S, Menzies D. Invasive aspergillosis in patients with chronic obstructive pulmonary diseases. Can Respir J 2005;12:199–204.PubMedGoogle Scholar
  80. 80.
    Calle F, Lopez J, Caillot D, Cuisenier B, Ecarnot LA, Dumont L, Bonnin A. False-positive results caused by cotton swabs in commercial Aspergillus antigen latex agglutination test. Eur J Clin Microbiol Infect Dis 2002;21:130–2.CrossRefGoogle Scholar
  81. 81.
    Boutboul F, Alberti C, Leblanc T, Sulahian A, Gluckman E, Derouin F, Ribaud P. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002;34:939–43.PubMedCrossRefGoogle Scholar
  82. 82.
    Pazos C, del Palacio A. Early diagnosis of invasive aspergillosis in neutropenic patients with bi-weekly serial screening of circulating galactomannan by Platelia Aspergillus. Rev Iberoam Micol 2003;20:99–102.PubMedGoogle Scholar
  83. 83.
    Maertens J, Glasmacher A, Selleslag D, Ngai A, Ryan D, Layton M, Raylor A, Sable C, Kartsonis N. Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. Clin Infect Dis 2005;41:e9–e14.PubMedCrossRefGoogle Scholar
  84. 84.
    Klont RR, Mennink-Kersten MA, Ruegebrink D, Rijs AJ, Blijlevens NM, Donnelly JP, Verweij PE. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis 2006;43:e23–e25.PubMedCrossRefGoogle Scholar
  85. 85.
    Chabot J, Twumasi-Boateng K, Patterson TF, Chiang LY, Filler SG, Sheppard DC. Effect of antifungal agents on galactomannan release. 2nd advances against aspergillosis (AAA). Athens, Greece; 2006: Poster 137.Google Scholar
  86. 86.
    Giacchino M, Chiapello N, Bezzio S, Fagioli F, Saracco P, Alfarano A, Martini V, Cimino G, Martino P, Girmenia C. Aspergillus galactomannan enzyme-linked immunosorbent assay cross-reactivity caused by invasive Geotrichum capitatum. J Clin Microbiol 2006;44:3432–4.PubMedCrossRefGoogle Scholar
  87. 87.
    Dalle F, Charles PE, Blanc K, Caillot D, Chavanet P, Dromer F, Bonnin A. Cryptococcus neoformans galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus galactomannan. J Clin Microbiol 2005;43:2929–31.PubMedCrossRefGoogle Scholar
  88. 88.
    Rimek D, Zimmermann T, Hartmann M, Prariyachatigul C, Kappe R. Disseminated Penicillium marneffei infection in an HIV-positive female from Thailand in Germany. Mycoses 1999;42 Suppl 2:25–8.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2007

Authors and Affiliations

  • Valério R. Aquino
    • 1
  • Luciano Z. Goldani
    • 2
  • Alesssandro C. Pasqualotto
    • 3
  1. 1.Mycology Laboratory, Service of Clinical PathologyHospital de Clínicas de Porto AlegreRio Grande do SulBrazil
  2. 2.Department of Internal MedicineUniversidade Federal do Rio Grande do SulRio Grande do SulBrazil
  3. 3.School of MedicineThe University of ManchesterManchesterUK

Personalised recommendations